Search

Displaying results 2941 - 2950 of 10000 in total
  1. Drug

    Gancotamab

    go.drugbank.com/drugs/DB14784
    Investigational

    Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs.

  2. Drug

    Belapectin

    go.drugbank.com/drugs/DB15125
    Investigational

    Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).

    Categories: Complex Mixtures
  3. Drug

    Farletuzumab ecteribulin

    go.drugbank.com/drugs/DB18857
    Investigational

    Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin),

  4. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  5. Drug

    Pamrevlumab

    go.drugbank.com/drugs/DB14952
    Investigational

    Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

  6. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.

  7. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  8. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation

  9. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].

  10. Drug

    Nifuratel

    go.drugbank.com/drugs/DB13724
    Investigational

    Mixtures: NİFUNİS 500 MG/200.000 I.U. VAJİNAL OVÜL, 6 ADET, NİFUNİS 500 MG/200.000 I.U. VAJİNAL OVÜL, 12 ADET